MedPath

Progesterone

Generic Name
Progesterone
Brand Names
Bijuva, Crinone, Endometrin, Prochieve, Prometrium
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
57-83-0
Unique Ingredient Identifier
4G7DS2Q64Y
Background

Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss . Progesterone is used in various contraceptive preparations to prevent ovulation and fertilization , as well as in other formulations to promote and support pregnancy. Please see Medroxyprogesterone acetate, Megestrol acetate, Dydrogesterone and Hydroxyprogesterone entries for information on various other forms of progesterone.

Pharmaceutical progesterone is made from a plant source as a starting material and is chemically identical to progesterone of human ovarian origin . Progesterone is available in gelatinized capsule form, vaginal gel form, tablet form, vaginal insert form, and injection form, all used for various purposes .

Indication

Gelatinized capsules

The gelatinized capsules are indicated for use in the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea .

Vaginal gel

Progesterone gel (8%) is indicated as progesterone supplementation or replacement as part of an Assisted Reproductive Technology (“ART”) treatment for infertile women with progesterone deficiency. The lower concentration progesterone gel (4%) is used in the treatment of secondary amenorrhea, with the use of the 8% concentration if there is no therapeutic response to the 4% gel .

Vaginal insert

This form is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women .

Injection (intramuscular)

This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer .

Tablets, contraceptive

The tablet form of progesterone in contraceptive formulations is indicated for the prevention of pregnancy .

Associated Conditions
Abnormal Uterine Bleeding, Amenorrhea, Endometrial hyperplasia caused by conjugated estrogen, Moderate to Severe Vasomotor Symptoms, Pregnancy, Secondary Amenorrhea, Recurrent spontaneous preterm birth
Associated Therapies
Assisted Reproductive Technology therapy

Comparison in Cervical Length and Prolongation of Gestation Age on Vaginal Progesterone Administration to Pregnant Women After the Acute Phase of Threatened Preterm Birth

Not Applicable
Active, not recruiting
Conditions
Pregnant Women
Pregnancies at Increased Risk of Preterm Birth
Interventions
First Posted Date
2025-05-16
Last Posted Date
2025-05-21
Lead Sponsor
Dr. Soetomo General Hospital
Target Recruit Count
48
Registration Number
NCT06975943
Locations
🇮🇩

Dr. Soetomo General Hospital Surabaya, Surabaya, East Java, Indonesia

Role of Low Dose Injectable Progesterone in Triggering Ovulation

Not Applicable
Recruiting
Conditions
Low Dose
Progesterone
Triggering Ovulation
Interventions
Drug: Placebo
First Posted Date
2025-04-15
Last Posted Date
2025-04-16
Lead Sponsor
The General Authority for Teaching Hospitals and Institutes
Target Recruit Count
120
Registration Number
NCT06928844
Locations
🇪🇬

Teaching Hospitals and Institutes, Cairo, Egypt

Is There a Need for Luteal Support in Modified Natural Cycle Frozen Embryo Transfer Cycles

Phase 4
Not yet recruiting
Conditions
Luteal Support
Frozen Embryo Transfer (FET)
Interventions
Drug: no luteal support
Drug: Progesterone plus HCG
First Posted Date
2025-03-13
Last Posted Date
2025-03-13
Lead Sponsor
Dunamenti REK Istenhegyi IVF Center
Target Recruit Count
180
Registration Number
NCT06875752

Comparison of Pregnancy Rates in Modified Natural Frozen Embryo Transfer (FET) Cycle After Luteal Support with GnRH Agonist Versus Progesterone

Early Phase 1
Not yet recruiting
Conditions
Ivf
Frozen Embryo Transfer (FET)
Interventions
First Posted Date
2025-03-11
Last Posted Date
2025-03-11
Lead Sponsor
Shaare Zedek Medical Center
Target Recruit Count
150
Registration Number
NCT06870266

Menopausal HT for Women Living With HIV (HoT)

Phase 4
Not yet recruiting
Conditions
HIV Infection
Menopause
Interventions
Drug: Placebo for estradiol gel
Drug: Placebo for micronized progesterone
First Posted Date
2025-03-04
Last Posted Date
2025-03-13
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Target Recruit Count
105
Registration Number
NCT06856174

Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency

Early Phase 1
Not yet recruiting
Conditions
Premature Ovarian Insufficiency
Interventions
Drug: Estrogen Patch
First Posted Date
2025-02-28
Last Posted Date
2025-05-21
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Target Recruit Count
185
Registration Number
NCT06851754
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome

Phase 4
Not yet recruiting
Conditions
Turner Syndrome
Primary Ovarian Insufficiency (Poi)
Interventions
Drug: Micronized Progesterone 100 MG
First Posted Date
2025-02-19
Last Posted Date
2025-04-13
Lead Sponsor
Children's Mercy Hospital Kansas City
Target Recruit Count
40
Registration Number
NCT06834594
Locations
🇺🇸

Children's Mercy Hospital, Kansas City, Missouri, United States

Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women with Polycystic Ovarian Syndrome

Completed
Conditions
Controlled Ovarian Hyperstimulation
Polycystic Ovarian Syndrome
Interventions
First Posted Date
2025-02-06
Last Posted Date
2025-02-25
Lead Sponsor
El Shatby University Hospital for Obstetrics and Gynecology
Target Recruit Count
100
Registration Number
NCT06812559
Locations
🇪🇬

ELShatby University Hospital, Alexandria, Egypt

Progesterone in Gender Affirming Hormone Therapy Study

Phase 2
Recruiting
Conditions
Transgender Women
Interventions
Drug: Placebo
First Posted Date
2025-02-04
Last Posted Date
2025-05-16
Lead Sponsor
Emory University
Target Recruit Count
40
Registration Number
NCT06807580
Locations
🇺🇸

Emory Transgender Clinic, Atlanta, Georgia, United States

Comparing the Pharmacokinetics of a Progesterone Ring Versus a Progesterone Vaginal Insert

Phase 1
Not yet recruiting
Conditions
Pre Term Birth
Interventions
First Posted Date
2024-11-01
Last Posted Date
2024-11-01
Lead Sponsor
Daré Bioscience, Inc.
Target Recruit Count
60
Registration Number
NCT06668896
© Copyright 2025. All Rights Reserved by MedPath